GuruFocus.com5d agoneutral
Novo Nordisk Stock Rises After GLP-1 Antitrust WinDismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
330last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
GuruFocus.com5d agoneutral
Lilly and Novo Win a Key GLP-1 Antitrust FightA Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.
Zacks21d agobearish
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters NowNovo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.
Simply Wall St.22d agobearish
Is Eli Lilly (LLY) Undervalued After Novo Nordisk’s GLP 1 Advertising Lawsuit?Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...
Motley Fool22d agobearish
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.
Stocktwits22d agobearish
Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro AdsNovo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.
GuruFocus.com86d agobullish
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure DrugBaxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.